• Parkinson Disease
    • Anthony Edward Lang
    • Anthony Edward Lang: Influence Statistics

      Anthony Edward Lang

      Anthony Edward Lang

      Show email address

      Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Division of Neurology, UHN, Division of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Anthony Edward Lang:Expert Impact

      Concepts for whichAnthony Edward Langhas direct influence:Parkinson disease,Parkinsons disease,Movement disorders,Subthalamic nucleus,Deep brain stimulation,Globus pallidus,Progressive supranuclear,Essential tremor.

      Anthony Edward Lang:KOL impact

      Concepts related to the work of other authors for whichfor which Anthony Edward Lang has influence:Parkinson disease,Deep brain stimulation,Subthalamic nucleus,Movement disorders,Basal ganglia,Essential tremor,Motor symptoms.

      KOL Resume for Anthony Edward Lang


      Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Division of Neurology, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada


      The Edmond J. Safra Program in Parkinson’s Disease, Toronto Western Hospital, Toronto, Canada


      Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, ON, Canada.

      Krembil Research Institute, University Health Network, Toronto, Ontario, Canada

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Anthony Edward Lang is among the top experts in the world.
      Concept World rank
      dyskinesia female follow #1
      psychogenic movement disorder #1
      gre specificity #1
      mupdrs active treatment #1
      rectal domperidone #1
      pardoprunox patients #1
      pairing subthalamic nucleus #1
      cbt tremor severity #1
      “park” genes #1
      clinical anthology #1
      icds amantadine #1
      neuroinflammation striatum #1
      rest cbi #1
      abnormal gait patients #1
      local dyskinesia #1
      study design patients #1
      videotutorial #1
      sporadic papt #1
      domains autonomic failure #1
      week earlystart #1
      carbidopa therapy #1
      authors mutational analysis #1
      noiselevel #1
      rasagiline treatment #1
      dystonia tardive dystonia #1
      association e4 allele #1
      parkinsonism rate #1
      limb development rats #1
      levodopa netherlands #1
      precept #1
      cerebellothalamocortical pathway #1
      dopaminergic gp #1
      c709ct #1
      movement abnormalities adults #1
      mbrs bradykinesia scores #1
      ex70ex73del #1
      msa clinical features #1
      bradykinesia scores mbrs #1
      fixed postural deformity #1
      psp mpsprs21 #1
      frontotemporal regions cvd #1
      criterion levodopa #1
      nonparkinsonian relatives #1
      nondyskinetic #1
      dopamine‐agonists #1
      precept study #1
      22q112ds parkinsons disease #1
      dyskinetic t30 #1
      clr151 #1
      symptoms updrs points #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Anthony Edward Lang

      KOL-Index: 19084

      BACKGROUND: The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear.

      OBJECTIVE: To compare initial treatment with pramipexole vs levodopa in early Parkinson disease, followed by levodopa supplementation, with respect to the development of dopaminergic motor complications, other adverse events, and functional and quality-of-life outcomes.

      DESIGN: Multicenter, parallel-group, double-blind, randomized controlled trial.

      SETTING: Academic movement disorders ...

      Known for Initial Treatment | Parkinson Disease | Pramipexole Levodopa | Dopaminergic Therapy | Randomized Controlled
      KOL-Index: 18793

      It is often difficult to differentiate clinically between Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). The objective of this work was to investigate whether combined pre- and postsynaptic dopaminergic single photon emission computed tomography (SPECT) scanning can reliably demonstrate changes in the nigrostriatal dopaminergic system and help differentiate between normal controls, PD, MSA, and PSP patients. We performed SPECT ...

      Known for Dopamine Transporter | Msa Psp | Posterior Putamen | Progressive Tomography | Receptor Spect
      KOL-Index: 17367

      BACKGROUND: The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. Here, we report additional secondary and post-hoc analyses of the ADAGIO study.

      METHODS: ADAGIO was a placebo-controlled, double-blind, multicentre, delayed-start study, in which 1176 patients with untreated early Parkinson's disease were randomly assigned to receive ...

      Known for Adagio Study | Updrs Scores | 36 Weeks | Rasagiline Placebo | Week Difference
      KOL-Index: 16813

      BACKGROUND: A therapy that slows disease progression is the major unmet need in Parkinson's disease.

      METHODS: In this double-blind trial, we examined the possibility that rasagiline has disease-modifying effects in Parkinson's disease. A total of 1176 subjects with untreated Parkinson's disease were randomly assigned to receive rasagiline (at a dose of either 1 mg or 2 mg per day) for 72 weeks (the early-start group) or placebo for 36 weeks followed by rasagiline (at a dose of either 1 ...

      Known for 1 Day | Updrs Score | Week Earlystart | Early Treatment | Rasagiline Parkinsons Disease
      KOL-Index: 15443

      BACKGROUND: There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist.

      METHODS: In this prospective, randomized, double-blind study, we compared the safety and efficacy of the dopamine D2-receptor agonist ropinirole with that of levodopa over a period of five years in 268 patients with early Parkinson's disease. If symptoms were not adequately controlled by the assigned study medication, patients could receive ...

      Known for Ropinirole Levodopa | Dyskinesia Patients | Early Parkinsons Disease | Initial Treatment | Aged Parkinson
      KOL-Index: 15239

      BACKGROUND: Increased neuronal activity in the subthalamic nucleus and the pars interna of the globus pallidus is thought to account for motor dysfunction in patients with Parkinson's disease. Although creating lesions in these structures improves motor function in monkeys with induced parkinsonism and patients with Parkinson's disease, such lesions are associated with neurologic deficits, particularly when they are created bilaterally. Deep-brain stimulation simulates the effects of a ...

      Known for Globus Pallidus | Subthalamic Nucleus | Pars Interna | Patients Parkinsons Disease | Motor Function
      KOL-Index: 15029

      Noninvasive brain stimulation studies have shown abnormal motor cortical plasticity in Parkinson's disease (PD). These studies used peripheral nerve stimulation paired with transcranial magnetic stimulation (TMS) to primary motor cortex (M1) at specific intervals to induce plasticity. Induction of cortical plasticity through stimulation of the basal ganglia (BG)-M1 connections has not been studied. In the present study, we used a novel technique of plasticity induction by repeated ...

      Known for Cortical Plasticity | Subthalamic Nucleus | Transcranial Magnetic | Dbs Tms | Parkinsons Disease
      KOL-Index: 14777

      This study examines the effect of apomorphine (APO), a nonselective D(1)- and D(2)-dopamine receptor agonist, on the firing activity of neurons in the subthalamic nucleus (STN) and internal segment of the globus pallidus (GPi) in patients with Parkinson's disease (PD). Single-unit microelectrode recordings were conducted in 13 patients undergoing implantation of deep brain stimulation electrodes in STN and 6 patients undergoing a pallidotomy. Doses of APO (2.5-8 mg) were sufficient to ...

      Known for Globus Pallidus | Subthalamic Nucleus | Gpi Stn | Neurons Patients | Firing Rate
      KOL-Index: 14504

      BACKGROUND: Mutations in LRRK2, the gene that encodes leucine-rich repeat kinase 2, are a cause of Parkinson's disease (PD). The International LRRK2 Consortium was established to answer three key clinical questions: can LRRK2-associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2?

      METHODS: Researchers from 21 ...

      Known for Mutations Lrrk2 | National Institute | Genetic Penetrance | Parkinson Disease | Motor Symptoms
      KOL-Index: 14271

      Parkinsonism, as a gradually progressive disorder, has a prodromal interval during which neurodegeneration has begun but cardinal manifestations have not fully developed. A systematic direct assessment of this interval has never been performed. Since patients with idiopathic REM sleep behaviour disorder are at very high risk of parkinsonism, they provide a unique opportunity to observe directly the development of parkinsonism. Patients with idiopathic REM sleep behaviour disorder in an ...

      Known for Behaviour Disorder | Rem Sleep | Disease Prodromal | Purdue Pegboard | Patients Parkinsonism
      KOL-Index: 13752

      The ability to dynamically use various aspects of cognition is essential to daily function, and reliant on dopaminergic transmission in cortico-striatal circuitry. Our aim was to investigate both striatal and cortical dopaminergic changes in patients with Parkinson's disease with mild cognitive impairment, who represent a vulnerable group for the development of dementia. We hypothesized severe striatal dopamine denervation in the associative (i.e. cognitive) region and cortical D2 ...

      Known for Mild Cognitive Impairment | Striatal Dopamine | Parkinsons Disease | Cortical Thickness | Patients Parkinson
      KOL-Index: 13660

      BACKGROUND: Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that its use might hasten neurodegeneration. This study assessed the effect of levodopa on the rate of progression of Parkinson's disease.

      METHODS: In this randomized, double-blind, placebo-controlled trial, we evaluated 361 patients with early Parkinson's disease who were assigned to receive carbidopa-levodopa at a daily dose of 37.5 and 150 mg, 75 and 300 mg, or ...

      Known for Levodopa Placebo | Progression Parkinsons Disease | Updrs Baseline | Daily Dose | 40 Weeks
      KOL-Index: 13609

      This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve ...

      Known for Clinimetric Testing | Movement Disorder Society | Rating Scale | Unified Parkinson | Mdsupdrs Updrs
      KOL-Index: 13212

      OBJECTIVE: The response of patients with dystonia to pallidal procedures is not well understood. In this study, we assessed the postoperative outcome of patients with primary and secondary dystonia undergoing pallidotomy or pallidal deep brain stimulation.

      METHODS: Fifteen patients with dystonia had pallidal surgery (lesions or deep brain stimulation). These included nine patients with primary dystonia (generalized and cervical dystonias) and six with secondary dystonia (generalized, ...

      Known for Primary Dystonia | Pallidal Deep | Brain Stimulation | Pallidus Humans | 6 Months

      Key People For Parkinson Disease

      Top KOLs in the world
      Andrew John Andrew
      parkinsons disease progressive supranuclear motor fluctuations
      Anthony Edward Lang
      parkinson disease movement disorders subthalamic nucleus
      Werner H Poewe
      parkinson disease multiple atrophy restless legs syndrome
      Christopher G Goetz
      parkinson disease movement disorders rating scales
      Charles W Olanow
      parkinson disease oxidative stress motor complications
      Joseph J Jankovic
      movement disorders parkinson disease essential tremor

      Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Division of Neurology, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada | Department of Me

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.